University of Minnesota

Hypertension Diagnostics, Inc.

Nitromed, Inc.

Other

Hypertension Diagnostic, Inc.

Jay N Cohn

Stanley M Finkelstein

Charles F Chesney

Dennis J Morgan

Christopher W Bratteli

Peter Carson

Screening apparently healthy individuals using sensitive techniques for identifying early vascular and cardiac disease provides the opportunity for effective intervention to prevent or delay the occurrence of cardiovascular events which represent the most common cause of morbidity and mortality in our society. Preliminary studies have revealed an incidence of over 50% of early disease in need of therapy. The apparent ineffectiveness of the health care system to uncover this early disease emphasizes the need for a more aggressive community approach to screen for early disease and to initiate therapy that should reduce health care costs and improve quality and duration of life.

Screening for early detection of cardiovascular disease in asymptomatic individuals

A system and method for dynamic multi-stage test administration for detection of cardiovascular disease may include performing a first set of tests in a first stage of testing on a patient. Physiological results for each of the tests in the first stage may then be received. Then, based on the physiological results, dynamically determining a set of tests to perform on the subject in a second stage of testing. Additionally, the dynamically determined set of tests in the second stage of testing may be performed on the subject.

System and method for dynamic multi-stage test administration for detection of cardiovascular disease

The present invention provides methods of treating and preventing mortality associated with heart failure in an African American patient with hypertension, and improving oxygen consumption, quality of life and exercise tolerance by administering a therapeutically effective amount of at least one hydralazine compound and at least one of isosorbide dinitrate and isosorbide mononitrate, and, optionally, one or more compounds, such as, for example, a digitalis, a diuretic compound, or a compound used to treat cardiovascular diseases. In the present invention, the hydralazine compound is preferably hydralazine or a pharmaceutically acceptable salt thereof. Preferred methods of the invention comprise administering hydralazine or a pharmaceutically acceptable salt thereof and isosorbide dinitrate.

Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate

Methods and apparatus for processing an arterial blood pressure waveform to extract clinically useful information on the state of the cardiovascular system are disclosed herein. In order to obtain the parameters of the modified Windkessel model, the diastolic portion of a subject's blood pressure waveform is scanned over a plurality of ranges and the range that produces the best fit of data and lowest error estimates are selected. In addition, multiple empirically determined starting values of the 'A' parameters are used to find the best fit of the model data to the actual arterial blood pressure waveform data.

Apparatus and method for blood pressure pulse waveform contour analysis

A vascular impedance measurement instrument includes a transducer to obtain a digitized arterial blood pressure waveform. The digitized data is used to determine cardiac output, and to subsequently obtain measurements of impedance parameters using the modified Windkessel model of the arterial system. The instrument is used as an aid in diagnosing, treating and monitoring patients with cardiovascular disease.

Method and instrument to measure vascular impedance

The present invention provides methods or treating and preventing mortality associated with heart failure in an African American patient with hypertension and improving oxygen consumption, quality of life and exercise tolerance by administering a therapeutically effective amount of at least one hydralazine compound and at least one of isosorbide dinitrate and isosorbide mononitrate, and, optionally, one or more compounds, such as, for example, a digitalis, a diuretic compound, or a compound used to treat cardiovascular diseases. In the present invention, the hydralazine compound is preferably hydralazine or a pharmaceutically acceptable salt thereof. Preferred methods of the invention comprise administering hydralazine or a pharmaceutically acceptable salt thereof and isosorbide dinitrate.

Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate

Vascular impedance measurement instrument

Methods and apparatus for processing an arterial blood pressure waveform to extract clinically useful information on the state of the cardiovascular system are disclosed herein. In order to obtain the parameters of the modified Windkessel model, the diastolic portion of a subject's blood pressure waveform is scanned over a plurality of ranges and the range that produces the best fit of data and lowest error estimates are selected. In addition, multiple empirically determined starting values of the `A` parameters are used to find the best fit of the model data to the actual arterial blood pressure waveform data.

Method for vascular impedance measurement

Apparatus for Measuring Stroke Volume/Cardiac Output includes a transducer for measuring arterial blood pressure waveform, a digitizer for digitizing the analog signal generated by the transducer and a digital signal processor for determining ejection time and heart rate. Processor circuitry determines cardiac output using the ejection time, heart rate, the body surface area and age of the patient, with the cardiac output measure being displayed by the meter.

Method and apparatus for measuring cardiac output

A method for diagnosing, monitoring and treating hypertension uses the parameter C.sub.2 of the modified Windkessel model as an indication of the hypertensive disease condition. Apparatus for determining the parameter C.sub.2 (i.e. distal vascular compliance) of the modified Windkessel model includes means for obtaining a pressure pulse contour and a cardiac output value and for determining the model parameters.

Growing community of inventors

Minneapolis, MN, United States of America

Jay N Cohn